Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13426054 | 0.95 | ALDH1A1 (0.62) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL7628596 | 0.92 | ALDH1A1 (0.70) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL7955008 | 0.91 | ALDH1A1 (0.68) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL3969095 | 0.91 | ALDH1A1 (0.72) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL17599857 | 0.89 | ALDH1A1 (0.66) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL12849347 | 0.89 | ALDH1A1 (0.66) | ALDH1A1CA12CA2CA9ALOX15 | |
| Hydrochloric Acid SCHEMBL11629317 | 0.88 | ALDH1A1 (0.64) | ALDH1A1CA12CA2CA9ALOX15 | |
| Hydrochloric Acid SCHEMBL5093423 | 0.88 | ALDH1A1 (0.64) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL12085676 | 0.87 | ALDH1A1 (0.67) | ALDH1A1HTTL3MBTL1LMNANPSR1 | |
| SCHEMBL7937849 | 0.86 | ALDH1A1 (0.62) | ALDH1A1CA12CA2CA9ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2019-07-16 | — | — | US | disclosed |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA, LLC | 2017-10-12 | — | — | US | disclosed |
| US-9616035-B2 | Pharmaceutical for oral delivery comprising MGBG and methods of treating disease | PATHOLOGICA, LLC (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA, LLC | 2015-12-17 | — | — | US | disclosed |
| WO-2014110154-A1 | METHODS AND COMP0STIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA LLC (US) | 2014-07-17 | — | — | WO | disclosed |
| US-8779195-B2 | Polyamine derivatives | NIHON UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8779195-B2 | Polyamine derivatives | NIHON UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20140051765-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20120289604-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8258186-B2 | Pharmaceutical for oral delivery comprising MGBG | PATHOLOGICA, LLC (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110112199-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2011009039-A2 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20100063322-A1 | NOVEL POLYAMINE DERIVATIVES | NIHON UNIVERSITY (JP) | 2010-03-11 | — | — | US | disclosed |
| US-5866613-A | Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5342945-A | Bis-hexahydropyrimidinylakyl compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1994-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063322-A1 | NOVEL POLYAMINE DERIVATIVES | SRM, SMS, H1-3 | ALDH1A1 3019/4885CA12 2932/4885CA2 1327/4885 |
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | SRM, PMP22, SMS | ALDH1A1 2747/4885CA12 4738/4885CA2 4344/4885 |
| US-20140051765-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | ALDH1A1 1462/4885CA12 2977/4885CA2 3322/4885 |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | ALDH1A1 1462/4885CA12 2977/4885CA2 3322/4885 |
| US-20120289604-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | ALDH1A1 1462/4885CA12 2977/4885CA2 3322/4885 |
| US-20110112199-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | ALDH1A1 1462/4885CA12 2977/4885CA2 3322/4885 |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PMP22, MAG, GMFG | ALDH1A1 2637/4885CA12 1122/4885CA2 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.